Head-to-head evidence
Crexont (IPX203) vs TR-012001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Crexont (IPX203)
Marketed by Amneal Pharmaceuticals
NCT03670953 · Phase 3 · completed
The study was randomized, quadruple-blind, double-dummy, and active-controlled, with 506 participants entering the randomized maintenance period and 495 contributing primary-endpoint data. The clinical primary endpoint was met: IPX203 produced a significantly greater improvement in daily “good on” time than immediate-release carbidopa-levodopa (p=0.0194).
Next expected readout: December 2026 · NCT07138560 (registry estimate)
TR-012001
Developed by SNLD, Ltd.
NCT06212089 · Phase 2 · completed
The study randomly assigned 12 participants to TR-012001 or placebo and masked participants, but it was single-blind and very small. Because no results are posted, it cannot establish whether the primary safety comparisons were favorable or statistically significant.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Crexont (IPX203)'s landscape · TR-012001's landscape